Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 95.4%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 153,400 shares, an increase of 95.4% from the March 31st total of 78,500 shares. Based on an average daily volume of 648,100 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer raised Avalo Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, April 16th.

Avalo Therapeutics Stock Performance

AVTX traded up $0.96 during midday trading on Friday, reaching $15.94. The company had a trading volume of 78,226 shares, compared to its average volume of 296,189. Avalo Therapeutics has a 12-month low of $3.95 and a 12-month high of $1,130.40. The business has a 50-day moving average price of $9.42 and a two-hundred day moving average price of $13.33. The stock has a market cap of $16.48 million, a PE ratio of -0.03 and a beta of 1.15.

Institutional Investors Weigh In On Avalo Therapeutics

An institutional investor recently bought a new position in Avalo Therapeutics stock. Acadian Asset Management LLC bought a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 283,306 shares of the company’s stock, valued at approximately $34,000. Acadian Asset Management LLC owned 1.40% of Avalo Therapeutics at the end of the most recent reporting period. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.